AstraZeneca

AZN

Drug Manufacturers - General · Healthcare

Price

$168.90

-0.39 (-0.23%)

Market Cap

$130.97B

Exchange

New York Stock Exchange

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Share count rising — dilution

+9.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 713.5M (2021) → 781.0M (2025)

AstraZeneca is a global pharmaceutical company that discovers, makes, and sells prescription medicines. Its main products include cancer drugs like Tagrisso and Enhertu, heart and kidney medicines like Farxiga, and respiratory treatments like Symbicort. It sells primarily to hospitals, clinics, and pharmacies, with patients and healthcare systems as the end users.

The company earns money by selling branded prescription drugs, which carry high prices protected by patents. AstraZeneca operates in over 100 countries, with major revenue coming from the US, Europe, and a fast-growing China business. Its competitive edge comes from a strong oncology pipeline and deep research partnerships, but patent expirations on key drugs remain a persistent risk — when patents expire, cheaper generic versions can quickly erode sales. The company's ability to keep launching new cancer and rare-disease treatments from its pipeline will be the main factor driving future growth.

Winston Score History

Politician Trades

11 trades / 12mo

7 Congressional buys and 4 sells on AZN in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+12.5% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+5.9% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$14.2B/ year

→ Flat (+5% vs prior year)

24.2% of revenue

In line with sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.6%ownership

Relatively low insider ownership

Cash Position

Cash flow positive

$11.9B cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

AstraZeneca is a rare growth stock that's already generating positive cash flow while growing at 13%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

82.5%

Premium pricing power — 82.5% gross margin

Operating Margin

27.8%

Excellent — 27.8% operating margin

ROCE

5.4%

Weak — 5.4% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+9.9%

Steady sales growth (9.9% YoY)

EPS YoY

+33.9%

Earnings growing fast (33.9% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

138%

Turns 138% of profit into real cash

FCF Margin

13.3%

Converts sales into free cash efficiently (13.3%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.68

Moderate — manageable debt (0.68)

Interest Cover

8.24x

Comfortably covers interest (8.2x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

25.2x

Growth-priced — P/E 25.2

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

+10.3

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (25.2 → 14.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

1.62%

Small dividend — 1.62% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth

+47.6%

Dividend growing fast (47.6% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial